-

Shareholder Alert: Robbins LLP Announces Hanmi Financial Corporation (HAFC) Sued for Misleading Shareholders

SAN DIEGO & LOS ANGELES--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Hanmi Financial Corporation (NASDAQ: HAFC) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 12, 2019 and January 28, 2020. Hanmi operates as the holding company for Hanmi Bank, which provides business banking products and services in the United States.

If you suffered a loss as a result of Hanmi's misconduct, click here.

Hanmi Financial Corporation (HAFC) Accused of Misleading Shareholders

According to the complaint, on August 12, 2019, Hanmi announced that it would be unable to timely file its quarterly report due to an evaluation of "the classification of a single $40.7 million credit relationship… and the related adjustment to the allowance for loan and lease losses." Hanmi acknowledged the review could affect the financial statements included in the report and could indicate a possible internal control deficiency related to construction lending, but failed to disclose that the troubled loan could lead to future provisions in the millions. Then, on January 28, 2020, Hanmi reported net income of $3.1 million for the quarter, including an additional "$6.9 million specific provision for loan and lease losses related to a previously identified $39.7 million troubled loan relationship." To secure the loan relationship, Hanmi disclosed that the Company "received current appraisals on the personal property… and have provided for a specific allowance in the lower range of the appraised values." On this news, Hanmi's stock price fell almost 10% to close at $16.99 per share.

Hanmi Financial Corporation (HAFC) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:HAFC

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Wil...

Investor Notice: Robbins LLP Informs Investors of the Eos Energy Enterprises, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a n...
Back to Newsroom